ERBB2 and breast carcinoma: Efficacy data from this study compare favorably with response rates in studies of single agent cytotoxics (capecitabine [35], vinorelbine [36], eribulin [37], ixabepilone [38–40]) and of new anti-HER2 targeted therapies (pertuzumab [41] and T-DM1 [42]) in advanced breast cancer treatment.